FIELD: pharmaceutical industry. SUBSTANCE: desired purified derivative represents sulfoalkyl ether of cyclodextrine; desired clathrate complex comprises cyclodextrine and drug at their molar ratio from 10:1 to 1:10, respectively. Pharmaceutical composition comprises pharmaceutically acceptable carrier and mentioned above clathrate complex, its quantity being 1-750 mg per dose. EFFECT: improved quality of desired product. 4 cl, 6 tbl, 14 dwg
Authors
Dates
1997-12-20—Published
1992-07-22—Filed